Protagonist Therapeutics Announces the Appointment of Newman Yeilding, MD, as Chief Scientific Advisor

We are honored to continue our work with Protagonist Therapeutics, recruiting I&I R&D leader, Newman Yeilding, MD, as the Company’s Chief Scientific Advisor. Throughout his career, including 17 years with Janssen, Dr. Yeilding has successfully championed multiple novel programs through research, development and commercialization in rheumatology, gastroenterology, dermatology, and pediatrics. Dr. Yeilding served as Janssen’s Head of Immunology Development; Vice President of Immunology, Dermatology, and GI Development; Vice President of Immunology, STELARA and Early Development Compound Development Team Leader. He led an R&D organization of approximately 250 members in close collaboration with the Immunology Global Strategic Commercial Organization to accelerate development, commercialization, and market access of innovative first-in-class or best-in-class compounds for the global Immunology market. Prior to Janssen, he was the Associate Director of Medical Affairs at Centocor and served as Chief of Hematology-Oncology at the Philadelphia Veterans Administration Medical Center, after spending four years as a research track faculty with research focused on tumor angiogenesis. Dr. Yeilding earned his MD from the University of Alabama, Birmingham, and a BS from Davidson University in North Carolina.